http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101837736-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0021 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-08 |
| filingDate | 2017-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101837736-B1 |
| titleOfInvention | Novel compounds having GPR40 agonistic activity and use thereof |
| abstract | The present invention relates to a novel compound having GPR40 agonist activity and a pharmaceutical composition for preventing or treating diabetes comprising the compound as an active ingredient. The novel compound or a pharmaceutically acceptable salt thereof according to the present invention is a GPR40 agonist that increases the secretion of Ca 2+ to promote the secretion of intracellular insulin and the prevention or treatment of diabetes by controlling blood glucose Bar, and prevention or control of diabetes. |
| priorityDate | 2016-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 292.